Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms

IntroductionThe phase 3 CLEAR study demonstrated that lenvatinib plus pembrolizumab significantly improved efficacy versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (RCC). Prognostic features including presence and/or site of baseline metastases, prior nephrec...

Full description

Bibliographic Details
Main Authors: Viktor Grünwald, Thomas Powles, Masatoshi Eto, Evgeny Kopyltsov, Sun Young Rha, Camillo Porta, Robert Motzer, Thomas E. Hutson, María José Méndez-Vidal, Sung-Hoo Hong, Eric Winquist, Jeffrey C. Goh, Pablo Maroto, Tomas Buchler, Toshio Takagi, Joseph E. Burgents, Rodolfo Perini, Cixin He, Chinyere E. Okpara, Jodi McKenzie, Toni K. Choueiri
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Oncology
Subjects:
renal cell carcinoma
lenvatinib
pembrolizumab
sunitinib
bone metastases
liver metastases
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1223282/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1223282/full

Similar Items